

# Juan Luis Steegmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6127871/publications.pdf>

Version: 2024-02-01

58  
papers

513  
citations

759233

12  
h-index

713466

21  
g-index

59  
all docs

59  
docs citations

59  
times ranked

879  
citing authors

#	ARTICLE	IF	CITATIONS
1	Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2351-2361.	1.3	90
2	Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. <i>Haematologica</i> , 2017, 102, 103-109.	3.5	52
3	Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner. <i>Clinical Cancer Research</i> , 2017, 23, 6697-6707.	7.0	41
4	Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. <i>Haematologica</i> , 2003, 88, 762-8.	3.5	36
5	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1585-1596.	2.5	29
6	ABLO01, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single-Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. <i>Blood</i> , 2015, 126, 138-138.	1.4	22
7	Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2019, 98, 321-330.	1.8	21
8	Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program. <i>American Journal of Hematology</i> , 2015, 90, 429-433.	4.1	19
9	Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?. <i>Annals of Hematology</i> , 2018, 97, 2089-2098.	1.8	18
10	Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data. <i>Blood</i> , 2012, 120, 1675-1675.	1.4	18
11	Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6506-6506.	1.6	15
12	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. <i>Biochemical Pharmacology</i> , 2018, 156, 248-264.	4.4	14
13	Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response. , 1998, 59, 95-97.		13
14	Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 1340.	3.5	11
15	ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase. <i>Blood</i> . 2016. 128. 3094-3094.	1.4	11
16	The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.. <i>Blood</i> , 2009, 114, 4272-4272.	1.4	11
17	Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. <i>Biochemical Pharmacology</i> , 2020, 182, 114203.	4.4	9
18	PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. <i>PLoS ONE</i> , 2017, 12, e0181366.	2.5	8

#	ARTICLE	IF	CITATIONS
19	Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials. <i>Blood</i> , 2013, 122, 1489-1489.	1.4	8
20	Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC). <i>Blood</i> , 2012, 120, 3764-3764.	1.4	8
21	Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase. <i>Blood</i> , 2015, 126, 4040-4040.	1.4	7
22	Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?. <i>American Journal of Hematology</i> , 2014, 89, E206-11.	4.1	6
23	An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2059-2066.	2.5	6
24	Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1217-1224.	2.8	5
25	Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposure and study of hypopigmentation as treatment's prognostic factor. <i>Dermatologic Therapy</i> . 2020, 33, e14428.	1.7	4
26	Smoothed inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study. <i>Leukemia and Lymphoma</i> , 2021, 62, 739-742.	1.3	3
27	Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study. <i>Blood</i> , 2013, 122, 4030-4030.	1.4	3
28	Bosutinib Appears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program. <i>Blood</i> , 2014, 124, 5523-5523.	1.4	3
29	The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 595-595.	1.4	3
30	Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy. <i>Blood</i> , 2008, 112, 573-573.	1.4	3
31	Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7054-7054.	1.6	3
32	EUTOS Score Is Also Valid in CML Patients Not Involved in Clinical Studies. <i>Blood</i> , 2012, 120, 3759-3759.	1.4	2
33	Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials. <i>Blood</i> , 2014, 124, 3160-3160.	1.4	2
34	Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data. <i>Blood</i> , 2014, 124, 3145-3145.	1.4	2
35	Treatment of Chronic Myeloid Leukemia Relapsing After Allogeneic Bone Marrow Transplantation: The Case for Giving Interferon. <i>Blood</i> , 1998, 91, 2617-2619.	1.4	1
36	Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients. <i>Blood</i> , 2018, 132, 47-47.	1.4	1

#	ARTICLE	IF	CITATIONS
37	CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry. <i>Blood</i> , 2013, 122, 2735-2735.	1.4	1
38	Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method. <i>Blood</i> , 2015, 126, 2776-2776.	1.4	1
39	Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis. <i>Blood</i> , 2015, 126, 479-479.	1.4	1
40	Safety and Efficacy of Dasatinib Treatment Change for Patients Previously Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study. <i>Blood</i> , 2016, 128, 5450-5450.	1.4	1
41	Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the "Watch and Wait" Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials. <i>Blood</i> , 2012, 120, 3768-3768.	1.4	1
42	Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.. <i>Blood</i> , 2009, 114, 1121-1121.	1.4	0
43	Newly acquired chromosome Abnormalities During Course of CLL: a Retrospective Collection Data From 2 Spanish Centers.. <i>Blood</i> , 2009, 114, 4384-4384.	1.4	0
44	Transforming and Tumorigenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosin-Kinase.. <i>Blood</i> , 2009, 114, 4683-4683.	1.4	0
45	Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC). <i>Blood</i> , 2010, 116, 1237-1237.	1.4	0
46	Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE); Tj ETQq0 0 0 rgB4/Overlook 10 Tf 50	1.4	0
47	Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry. <i>Blood</i> , 2011, 118, 1688-1688.	1.4	0
48	A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials. <i>Blood</i> , 2012, 120, 3762-3762.	1.4	0
49	Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7053-7053.	1.6	0
50	NK-Cells In Dasatinib-Treated Chronic Myeloid Leukemia Patients Display a Unique Phenotype Associated With Cytotoxic Potential. <i>Blood</i> , 2013, 122, 1475-1475.	1.4	0
51	Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predictive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial. <i>Blood</i> , 2013, 122, 5190-5190.	1.4	0
52	Treatment of Chronic Myeloid Leukemia Relapsing After Allogeneic Bone Marrow Transplantation: The Case for Giving Interferon. <i>Blood</i> , 1998, 91, 2617-2619.	1.4	0
53	Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase. <i>Blood</i> , 2015, 126, 2791-2791.	1.4	0
54	Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2015, 126, 2786-2786.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis. Blood, 2015, 126, 4054-4054.	1.4	0
56	Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression. Blood, 2015, 126, 4015-4015.	1.4	0
57	The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method. Blood, 2016, 128, 1906-1906.	1.4	0
58	Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain. Blood, 2016, 128, 3074-3074.	1.4	0